Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Ranolazine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN5A known ✓ | Q14524 | 1/20 | 0.87 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.87 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.87 |
| ▸ | TSHR | P16473 | 1/20 | 0.87 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.87 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.87 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.87 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.87 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.87 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.87 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.87 |
| ▸ | DRD3 | P35462 | 1/20 | 0.87 |
| ▸ | HTR2B | P41595 | 1/20 | 0.87 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.87 |
| ▸ | LMNA | P02545 | 4/20 | 0.85 |
| ▸ | BLM | P54132 | 1/20 | 0.85 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.85 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.85 |
| ▸ | MEN1 | O00255 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ranolazine SCHEMBL12601020 | 1.00 | CYP3A4 (0.87) | CYP3A4CYP2D6TSHRNFKB1ADRB2 | |
| Ranolazine SCHEMBL13991211 | 0.95 | CYP3A4 (0.79) | CYP3A4CYP2D6TSHRNFKB1ADRB2 | |
| Ranolazine SCHEMBL12601019 | 0.95 | CYP3A4 (0.79) | CYP3A4CYP2D6TSHRNFKB1ADRB2 | |
| Ranolazine SCHEMBL1495098 | 0.93 | CYP3A4 (1.00) | CYP3A4CYP2D6TSHRNFKB1ADRB2 | |
| Ranolazine SCHEMBL30296819 | 0.93 | CYP3A4 (1.00) | CYP3A4CYP2D6TSHRNFKB1ADRB2 | |
| Ranolazine SCHEMBL7933344 | 0.93 | CYP3A4 (1.00) | CYP3A4CYP2D6TSHRNFKB1ADRB2 | |
| Ranolazine SCHEMBL6391141 | 0.93 | CYP3A4 (1.00) | CYP3A4CYP2D6TSHRNFKB1ADRB2 | |
| Ranolazine SCHEMBL1534086 | 0.93 | CYP3A4 (1.00) | CYP3A4CYP2D6TSHRNFKB1ADRB2 | |
| Ranolazine SCHEMBL124666 | 0.93 | CYP3A4 (1.00) | CYP3A4CYP2D6TSHRNFKB1ADRB2 | |
| Ranolazine SCHEMBL124665 | 0.93 | CYP3A4 (1.00) | CYP3A4CYP2D6TSHRNFKB1ADRB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260027111-A1 | METHODS OF TREATMENT | Bow River LLC (US) | 2026-01-29 | — | — | US | disclosed |
| US-12453730-B2 | Methods of treatment | Bow River LLC (US) | 2025-10-28 | — | — | US | disclosed |
| US-20250213557-A1 | METHODS OF TREATMENT | Bow River LLC | 2025-07-03 | — | — | US | disclosed |
| US-12318384-B2 | Methods of treatment | Bow River LLC (US) | 2025-06-03 | — | — | US | disclosed |
| US-20250032482-A1 | METHODS OF TREATMENT | Bow River LLC | 2025-01-30 | — | — | US | disclosed |
| EP-4461298-A2 | METHODS OF TREATMENT WITH CYP3A4 SUBSTRATE DRUGS | Bow River LLC (US) | 2024-11-13 | — | — | EP | disclosed |
| EP-3716976-B1 | METHODS OF TREATMENT WITH CYP3A4 SUBSTRATE DRUGS | Bow River LLC (US) | 2024-08-07 | — | — | EP | disclosed |
| US-11974998-B2 | Methods of treatment | Bow River LLC (US) | 2024-05-07 | — | — | US | disclosed |
| US-11857548-B2 | Methods of treatment | Bow River LLC (US) | 2024-01-02 | — | — | US | disclosed |
| US-20230414607-A1 | METHODS OF TREATMENT | Bow River LLC | 2023-12-28 | — | — | US | disclosed |
| US-11491152-B2 | Methods of treating lung cancer with CYP3A4 substrate drugs | Bow River LLC (US) | 2022-11-08 | — | — | US | disclosed |
| US-11419860-B2 | Methods of treatment | Bow River LLC (US) | 2022-08-23 | — | — | US | disclosed |
| US-20220249459-A1 | METHODS OF TREATMENT | Bow River LLC (US) | 2022-08-11 | — | — | US | disclosed |
| US-20220211685-A1 | METHODS OF TREATMENT | Bow River LLC | 2022-07-07 | — | — | US | disclosed |
| US-11351160-B2 | Methods of treating cancer | Bow River LLC (US) | 2022-06-07 | — | — | US | disclosed |
| US-11337967-B2 | Methods of treatment | Bow River LLC (US) | 2022-05-24 | — | — | US | disclosed |
| US-20220143011-A1 | METHODS OF TREATMENT WITH CYP3A4 SUBSTRATE DRUGS | Bow River LLC | 2022-05-12 | — | — | US | disclosed |
| US-7943620-B2 | Anti-anginal compounds | CONCERT PHARMACEUTICALS, INC. (US) | 2011-05-17 | — | — | US | disclosed |
| US-20080318969-A1 | Anti-anginal compounds | SUN PHARMACEUTICAL INDUSTRIES, INC. | 2008-12-25 | — | — | US | disclosed |
| US-20080312247-A1 | SUBSTITUTED PIPERAZINES | AUSPEX PHARMACEUTICALS, INC. (US) | 2008-12-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080312247-A1 | SUBSTITUTED PIPERAZINES | SCN2A, SCN5A, SCN1B | SCN5A 2/4885CYP3A4 1194/4885CYP2D6 1129/4885 |
| US-20260027111-A1 | METHODS OF TREATMENT | BRCA1, CYP2C19, CYP19A1 | SCN5A 3877/4885CYP3A4 11/4885CYP2D6 4/4885 |
| US-20080318969-A1 | Anti-anginal compounds | SQLE, ACSL5, ACSL1 | SCN5A 49/4885CYP3A4 1104/4885CYP2D6 689/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.